 Zynerba Pharmaceuticals NASDAQ:ZYNE Inc has reported results for the first quarter that reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel ZYN002. As of March 31, 2022, the Devon, Pennsylvania-based company increased its cash and equivalents to 69.7 million, compared to 67.8 million at the end of December 2021. 